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Nanomedicines (NMs) offer new solutions for cancer diagnosis
and therapy. However, extension of progression-free interval and
overall survival time achieved by Food and Drug Administration-
approved NMs remain modest. To develop next generation NMs to
achieve superior anticancer activities, it is crucial to investigate
and understand the correlation between the physicochemical
properties of NMs (particle size in particular) and their interactions
with biological systems to establish criteria for NM optimization.
Here, we systematically evaluated the size-dependent biological
profiles of three monodisperse drug–silica nanoconjugates (NCs;
20, 50, and 200 nm) through both experiments and mathematical
modeling and aimed to identify the optimal size for the most
effective anticancer drug delivery. Among the three NCs investi-
gated, the 50-nm NC shows the highest tumor tissue retention
integrated over time, which is the collective outcome of deep tu-
mor tissue penetration and efficient cancer cell internalization as
well as slow tumor clearance, and thus, the highest efficacy
against both primary and metastatic tumors in vivo.
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Over the last two to three decades, consensus has been reachedthat the size of anticancer nanomedicines (NMs) plays
a pivotal role in determining their biodistribution, tumor pene-
tration, cellular internalization, and clearance from blood plasma
and tissues as well as excretion from body, and thus, it has sig-
nificant impact on overall therapeutic efficacy against cancers
(1–7). Although most clinically approved anticancer NMs have
size ranging from 100 to 200 nm (8, 9), recent studies showed
that anticancer NMs with smaller sizes exhibited enhanced per-
formance in vivo, such as greater tissue penetration and en-
hanced tumor inhibition, particularly those with size around or
smaller than 50 nm (5–7, 10–12). As such, there has been a major
push recently in the field of anticancer NM to miniaturize
nanoparticle (NP) size using novel chemistry and engineering
design (13–17). One unanswered question, however, is whether
additional miniaturization of NM size would be necessary and
result in additional improved anticancer efficacy. Widely evalu-
ated small molecular therapeutics (<1,500 Da and <2 nm) can
traverse most tumor tissues freely (18). However, they diffuse
away from tumor tissues rapidly and get cleared primarily into
tumor blood capillaries, leading to minimal tumor accumulation
(18). Macromolecules of relatively low molecular masses
(<40,000 Da and <10 nm) were also shown to have low overall
tumor retention because of both rapid permeation into and
clearance from tumor tissues, behaving to some extent like small
molecule drugs (18, 19). In conjunction with the renal clearance
threshold (<10–15 nm) (20, 21) and interstitial/lymphatic fen-
estration (<20 nm) (22) for NPs, it becomes essential to carefully
and comprehensively evaluate the in vivo behavior and anti-
cancer efficacy of NMs in the size range of 20–50 nm to de-
termine the optimal size of NM for cancer therapy.
In this study, we used monodisperse drug–silica nanoconjugates
(NCs) that have identical physiochemical properties, except for
size, to investigate the size-dependent biodistribution and tumor
tissue penetration and clearance as well as the overall efficacy.
We focused on the NCs of 20 and 50 nm in this particularly
interesting size range as well as the NC of 200 nm, the upper size
limit of systemic NM to extravasate leaky tumor vasculature,
which has a cutoff pore size larger than 200 nm for most tumors
(23). Among these three representative sizes, the 50-nm NC
showed the optimal balance of deep tissue penetration and high
retention in tumors, which is in contrast with its larger coun-
terpart (the 200-nm NC) of limited tumor tissue penetration
and smaller counterpart (the 20-nm NC) of fast clearance from
tumors, leading to overall low tumor retention for both. There-
fore, 50 nm could be or could be close to the optimal size of NCs
in the studied size range of 20–200 nm, ensuring not only the
efficient distribution in, but also the protracted availability of
drug-containing NC to the tumor tissues, resulting in superior
anticancer efficacy against both primary and metastatic tumors.
Results and Discussion
To study the optimal size of NM for cancer therapy, we de-
veloped a precisely size-controlled NM, named drug–silica NC
(24). Silica NP is an attractive platform for the development of
NMs with excellently controlled sizes, high stability for biological
evaluations, and complete clearance and good safety profiles
for potential clinic applications (25–29). The designed drug–
silica NCs had a hard silica core and a drug-conjugated silica
outer layer with the surface coated with poly(ethylene glycol)
(PEG) (Fig. 1A). The silica cores with precisely controlled
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sizes were obtained by tuning the concentrations of tetraethyl
orthosilicate, alcohol, water, and ammonia using the Stöber
method (24). We conjugated camptothecin (Cpt), a cytotoxic
quinoline alkaloid that inhibits the DNA enzyme topoisomerase
I, to the size-controlled silica cores using a silanized derivative of
Cpt (Fig. 1A), yielding the Cpt-NCs with the desired sizes of 200,
50, and 20 nm in diameter (Cpt-NC200, Cpt-NC50, and Cpt-
NC20, respectively) (Fig. 1B). All three NCs had very narrow size
distribution measured by scanning electron microscope (SEM)
(Fig. 1B and Table 1) and dynamic light scattering (SI Appendix,
Fig. S1A). The coefficient of variation values were less than 10%,
indicating that the NCs were monodisperse by industrial stan-
dard (Table 1). These Cpt-NCs had similar drug loadings (15.9–
16.6 wt%), release kinetics, surface PEG densities (0.22–0.24
PEG molecules/nm2), ζ-potentials, and pharmacokinetics pro-
files in C57BL/6 mice (t1/2 = 3.0–3.2 h) (Table 1 and SI Appendix,
Fig. S1). Thus, the key physiochemical properties of these Cpt-
NCs were identical, leaving NP size as the only variable to be
studied for size impact on the interaction with biological systems.
With the highly controlled drug–silica NCs in hand, we first
examined the impact of NC size on biodistribution and tumor
tissue penetration as well as the outward clearance from tumors
to identify the optimal size of NC for highest tumor retention.
We first radiolabeled the 200-, 50-, and 20-nm silica NCs with
copper-64 (64Cu) cations (64Cu-NC200, 64Cu-NC50, and 64Cu-
NC20, respectively), administered them to athymic nude mice
bearing s.c. human MCF-7 tumors through i.v. injection, and
then, tracked their biodistribution with the PET imaging tech-
nique (Fig. 1C). Mice injected with 64Cu-NC50 had the highest
radioactivity in their tumor tissues among the three NCs tested
24 h postinjection (p.i.). This observation was confirmed by
quantification of the absolute radioactivity in the harvested tu-
mor tissues using a γ-counter, which showed that the 64Cu-NC50–
treated mice had 84.1% and 23.6% higher tumor accumulation
than 64Cu-NC200– and 64Cu-NC20–treated mice, respectively (Fig.
1D and SI Appendix, Fig. S2). By comparing the accumulation ratio
of tumor to muscle (Fig. 1E), we observed that smaller NCs
(≤50 nm) could passively target tumor tissues more efficiently
than larger NCs (200 nm), likely by the enhanced permeation and
retention effect (18, 23). Importantly, 64Cu-NC50 showed the
highest passive tumor targeting effect among the three NCs in the
MCF-7 human breast tumor model.
Fig. 1. Size-dependent biodistribution and tumor
retention of drug–silica NCs. (A) Schematic illustra-
tion of the size-controlled drug–silica NCs. (B) SEM
images of the Cpt-NCs. (C–E) In vivo biodistribution
of 64Cu-NCs of different sizes in athymic nude mice
bearing s.c. MCF-7 human breast tumors. The athy-
mic nude mice were injected i.v. with 64Cu-NC200,
64Cu-NC50, or 64Cu-NC20 and then euthanized 24 h
p.i. (n = 5). (C) Whole-body images were taken with
a micro-PET/computed tomography imaging system.
Yellow circles and arrows indicate the positions of
tumors. (D) Mouse organs, including tumors, were
collected and measured for radioactivity by γ-counter
to determine the %I.D. per gram values. (E) The
ratio of tumor to muscle was calculated based on
the %I.D. per gram values of tumor and muscle of
each mouse. All of the data are represented as the
average ± SEM and analyzed by one-way ANOVA
(Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).
(F) Monitoring of the kinetics of tumor accumula-
tion of 64Cu-NC50 and 64Cu-NC20 from 0 to 48 h p.i.
The AUC was calculated by the trapezoidal rule up
to 48 h. (G) Ex vivo tumor clearance study in MCF-7
tumors. MCF-7 tumors were ex vivo cultured with
Rhd-NCs of different sizes in opti-MEM for 24 h to
allow the silica NCs to penetrate into the tumors
passively and then immersed in fresh opti-MEM to
monitor the clearance of Rhd-NCs from the tumors.
After another 48 h, the tumors were sectioned and
imaged with a confocal fluorescence microscope.
Representative images show the retention of Rhd-NCs
(red) in tumor tissues. The nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI; blue). (Scale
bar: 50 μm.)
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We next focused on the 50- and 20-nm NCs to monitor their
kinetics of accumulation in the MCF-7 tumors in live mice non-
invasively over 48 h using dynamic PET (Fig. 1F). The radiation
signal increased rapidly in the tumors of the mice receiving 64Cu-
NC20 during the first 3 h p.i., likely because of the fast tumor
penetration of the 20-nm NC (24, 30). However, 64Cu-NC50 started
to show higher tumor accumulation than 64Cu-NC20 at 6 h p.i. and
persisted in tumors at higher levels until 48 h. The radiation signal
within the tumor tissue of the 64Cu-NC50–treated mice at 48 h p.i
was 1.4% of injected dose per gram of tissue (I.D./g), which was
70% higher than that of 64Cu-NC20–treated mice (0.82% I.D./g).
The area under curve (AUC) of 64Cu-NC50 was 1.52 times that of
20-nm NC over the 48-h period, suggesting that the 50-nm NC
maintained overall higher concentration in tumors. The overall
accumulation of the NCs in tumor depends on their extravasation
and permeation rate in tumor tissues and the effectiveness of cel-
lular internalization as well as the outward clearance from tumors.
Both 50- and 20-nm NCs were internalized by MCF-7 cells, which
was efficiently evidenced by an in vitro cell uptake experiment (SI
Appendix, Fig. S3A). The passive tumor penetration depths of
rhodamine (Rhd) -labeled 20-nm silica NC in MCF-7 tumor were
1.5- and 12.6-fold of that of Rhd-NC50 and Rhd-NC200, re-
spectively, as determined in an ex vivo experiment (SI Appendix, Fig.
S4), indicating that Rhd-NC20 could penetrate tumor tissues faster
and deeper. In an in vivo experiment, mice bearing s.c. MCF-7
tumors were i.v.-injected with Rhd-NCs, and the tumors were col-
lected 3 h p.i. for analyses. Indeed, more Rhd-NC20s were found in
tumor tissues farther away from tumor blood vessels than Rhd-
NC50 (SI Appendix, Fig. S5). These observations agree well with
previous reports (5, 24, 30). However, such rapid permeation
rate of 20-nm NC in the tumor interstitial space may lead to
a lower degree of tumor accumulation, because the smallest NC
(20 nm) can also be cleared faster from tumor tissues into blood
or lymphatic vessels as well as surrounding tissues than larger
NCs (19, 30). To compare the outward clearance rate, the
harvested MCF-7 and 4T1 tumors with preaccumulated Rhd-
NC50 or Rhd-NC20 in the tissues were immersed in fresh media
to monitor the amount of cleared silica NCs in the media (SI
Appendix, Fig. S6A). The results indicate that Rhd-NC20 was
cleared at a higher rate than Rhd-NC50 over the 48-h period (SI
Appendix, Fig. S6 B and C), resulting in less retention in the
tumor tissues (Fig. 1G). Fast and deep tumor penetration could
be the reason that 20-nm NC accumulated more in MCF-7
tumor tissues initially (first 3 h as shown in Fig. 1F). However,
the 50-nm NC was retained in tumors for longer dwell times
because of the relatively slower penetration into the tumor
interstitial space, with a resultant overall enhanced accumula-
tion in tumors over 48 h (Fig. 1 F and G). Therefore, 50 nm
could be the optimal size of NM that balances the extravasation
and permeation inside tumor tissues and the clearance from tu-
mor to retain the highest concentrations within the immediate tu-
mor and associated microenvironment.
To further develop insight into the size dependency of NM in
tumor accumulation and retention, we developed a mathematical
model of the spatiotemporal distribution of NPs within a spherically
symmetrical tumor. We modeled NP diffusion into and out of the
tumor spheroid, cell surface association and dissociation, and cel-
lular internalization and externalization. Model parameters were
fitted to experimental data of our silica NCs of 200, 50, and 20 nm
in diameter (24), and best fit linear regression models were used to
interpolate to NP sizes within this range (31–34). Full details of our
model, parameter fitting, and numerical solution techniques are
provided in SI Appendix. We solved our model for the spatiotem-
poral mass concentration of internalized NPs within a spherical
tumor with a radius of 3.5 mm over a time horizon of 48 h. In Fig. 2
A–C, we illustrate the predictions of our model for NPs of diameters
200, 50, and 20 nm. The precise structure of the spatiotemporal
concentration field results from the complex interplay of the NP
diffusive transport and cellular uptake kinetics. The radial pene-
tration of the NPs into the tumor spheroid is dictated in large part
by the NP mobility, with the reduced diffusivity of the larger NPs
resulting in a shallower depth of penetration. The temporal evolu-
tion of the profile is driven by the decay kinetics of the NPs in the
bulk, but it is also controlled by the transport, surface association,
and internalization of the NPs into cancer cells. The AUC of the
concentration of internalized NPs within the tumor is an important
parameter to compare the NP drug delivery effectiveness. In Fig.
2D, we present the model predictions of AUCs for 200, 50, and 20
nm NPs (AUC50 nm > AUC20 nm > AUC200 nm), which are in ex-
cellent agreement with the experimental results (Fig. 1 D–F). The
result suggests that the diffusivity and cellular uptake kinetics of the
50-nm NPs give rise to elevated dwell time within tumor tissue
relative to the 20- and 200-nm NPs.
To verify the optimal size identified by both experiment and
mathematical modeling, we next investigated whether the
enhanced tumor retention of 50-nm NM could directly impart
Table 1. Characterization of the size controlled drug–silica NCs
Name of NC D ± SD* (nm) CV%†
PEG density‡
(no./nm2)
Blood
half-life (h)
Cpt-NC200 199.3 ± 14.8 7.4 0.237 3.23
Cpt-NC50 53.2 ± 4.9 9.2 0.239 3.04
Cpt-NC20 24.9 ± 2.3 9.2 0.222 3.12
*The sizes of NCs were measured by SEM. Average diameter (D) and
standard deviation (SD) were calculated by measuring over 100 NCs in
SEM images.
†Coefficient of variation (CV%) = SD/D.
‡The number of PEG molecules per nanometer2 was calculated based on wt%
of PEG per NC and its surface area.
Fig. 2. Spatiotemporal modeling of size-dependent NP accumulation and re-
tention in tumors. (A–C) Predicted concentration fields for the mass of in-
ternalized NPs within a spherically symmetric tumor as a function of radial
distance from the tumor center (r) and time (t) for NPs of diameters of (A) 200,
(B) 50, and (C) 20 nm. Full details of the model specification, parameterization,
and solution are provided in SI Appendix. (D) Model predictions of the mass
of internalized NPs as a function of time for the three sizes of NPs over a
48-h time horizon. The ordinate of the plot records the mass of internalized
NPs within the spherical tumor, corresponding to the spatial integralR R
0 4πr
2drMiðt,rÞ, where R = 3.5 mm is the tumor radius, and Mi(t,r) is the
spatiotemporal mass concentration of internalized NPs within the tumor. The
AUC corresponds to the double integral
R T
0 dt
R R
0 4πr
2drMiðt,rÞ, where t = 48 h,
and it represents a proxy measure of NP effectiveness in accumulating within
the tumor. Both integrals are evaluated by numerical quadrature.
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amplified therapeutic efficacy in treating s.c.-implanted MCF-7
human breast tumors in athymic nude mice. MCF-7 is an estrogen-
dependent, noninvasive human breast cancer cell line that is
extensively studied as a xenograft model for ER+/HER2− breast
cancer (35). In an acute antitumor efficacy study, the mice
bearing MCF-7 tumors (initial tumor size was 49.3 mm3 on day
0) were treated i.v. with Cpt-NC200, Cpt-NC50, and Cpt-NC20
of 20 mg Cpt equivalent/kg three times on days 0, 4, and 8, and
PBS was used as a sham negative control group (SI Appendix,
Fig. S7 A and B). All mice were euthanized on day 12. The av-
erage tumor weight increased 23.5% in the PBS control group
over 12 d (SI Appendix, Fig. S7 C and D). As expected, Cpt-
NC200 showed very limited effect on tumor growth inhibition,
and the average tumor weight on day 12 remained nearly the
same as the original because of low tumor accumulation. Both
Cpt-NC50 and Cpt-NC20 were substantially more efficacious
than Cpt-NC200 and resulted in ∼50% tumor weight reduction
(SI Appendix, Fig. S7D). The tumors from all groups were ex-
cised, sectioned, and stained for Ki67 and terminal deoxy-
nucleotidyl transferase-mediated deoxyuridine triphosphate nick
end (TUNEL) to determine the proliferation index and apo-
ptosis index. The treatment with Cpt-NCs ≤ 50 nm resulted in
a significantly reduced proliferation index and an increased ap-
optosis index compared with Cpt-NC200 and Cpt-NC20 (Fig. 3
A–D). Cpt-NC50 reduced the proliferation index to 42.8 ± 2.6%,
which was significantly lower than both Cpt-NC200 (68.6 ±
0.9%) and Cpt-NC20 (50.5 ± 1.8%) (Fig. 3 A and C). Cpt-NC50
also triggered a significantly higher apoptosis index (21.0 ±
1.8%) than Cpt-NC200 (7.2 ± 0.3%) or Cpt-NC20 (15.3 ± 1.2%)
(Fig. 3 B and D). Together, Cpt-NC50 showed the highest effi-
cacy against MCF-7 tumors with an apoptosis-to-proliferation
index ratio of 61.4 ± 4.8%, which was 6.0- and 2.1-fold higher
than those of Cpt-NC200 (10.2 ± 0.5%) and Cpt-NC20 (28.6 ±
2.2%) (Fig. 3E).
To evaluate the tumor growth inhibition effect by Cpt-NCs of
various sizes over a longer period, a separate efficacy study was
designed similarly, except for adding blank silica NP (negative
control) and irinotecan (positive control) as the control groups
(SI Appendix, Fig. S8 A and B). Irinotecan was administered i.p.
at 100 mg/kg, which was dosed five times higher than Cpt-NCs
(20 mg/kg) (36). Compared with the PBS and the blank NP
negative control groups, all other treatment groups showed su-
perior growth inhibition of the MCF-7 tumor (Fig. 3F and SI
Appendix, Fig. S8C). Mice that received Cpt-NCs or irinotecan
also showed improved survival probability and increased median
duration of time to end point (Fig. 3 G and H). Cpt-NC50 and
Cpt-NC20 improved survival times by 76.5% and 61.8%, re-
spectively, with significantly longer time to end point than that of
Cpt-NC200. Importantly, among the Cpt-NCs of three different
sizes, Cpt-NC50 was the most efficacious in terms of tumor
growth inhibition and survival improvement. Interestingly, Cpt-
NC50 showed significantly higher efficacy compared with Cpt-
NC200 starting as early as day 6 (SI Appendix, Fig. S8C), whereas
the statistical significance between Cpt-NC20 and Cpt-NC200
appeared after 18 d of experimentation. Treatment with Cpt-
NC50 resulted in markedly smaller mean tumor burden (107 ±
13 mm3) at day 40 compared with Cpt-NC200 (261 ± 46 mm3)
and Cpt-NC20 (228 ± 42 mm3) (Fig. 3F), providing definitive
evidence that Cpt-NC50 is the most effective in reducing tumor
burden among all three NCs tested. There was no statistically
significant difference for tumor sizes or survival rates between
the Cpt-NC50 and the irinotecan groups. No significant changes
of body weight and food intake were observed for the mice in all
of the Cpt-NC groups (SI Appendix, Fig. S9). However, treatment
with irinotecan produced higher toxicity in mice, which was
evidenced by the notable body weight drop during the course of
the study (SI Appendix, Fig. S9A). Thus, Cpt-NC50 was able to
exert comparable anticancer activities as free irinotecan with
Fig. 3. Size-dependent antitumor efficacy in a primary tumor model. (A–E)
In an acute efficacy study, athymic nude mice bearing MCF-7 human breast
tumors were treated three times (every 4 d) by i.v. injection of PBS (1×), Cpt-
NC200 (20 mg Cpt/kg), Cpt-NC50 (20 mg Cpt/kg), or Cpt-NC20 (20 mg Cpt/kg)
on days 0, 4, and 8. (A and C) The collected MCF-7 tumors (n = 20) were
sectioned and further stained with Ki67 to analyze the proliferation index of
the tumor tissues. (A) Representative images and (C) quantification of Ki67
stains are shown. (B and D) The MCF-7 tumors (n = 20) were also stained with
TUNEL (green) and DAPI (blue) for apoptosis analyses of the tumor tissues.
(B) Representative images and (D) quantification by ImageJ of TUNEL stains
are shown. (Scale bar: A and B, 100 μm.) (E) The ratio of apoptosis index to
proliferation index indicates the overall efficacy of the Cpt-NCs. (F–H) In
a long-term efficacy study, athymic nude mice bearing MCF-7 tumors were
treated three times (every 4 d) by i.v. injection of PBS (1×), blank silica NPs,
Cpt-NC200 (20 mg Cpt/kg), Cpt-NC50 (20 mg Cpt/kg), or Cpt-NC20 (20 mg
Cpt/kg) on days 0, 4, and 8. Irinotecan (100 mg/kg) was administrated i.p.
on days 0, 7, and 14. (F ) Average tumor sizes of each group were mon-
itored over the course of the study (n = 20). (G) Kaplan–Meier plots for
all groups are shown. Loss of mice was because of treatment-related
death, nontreatment-related death, or euthanasia after the end point
(400 mg) had been reached (n = 5). (H) Survival analysis of the athymic
nude mice bearing MCF-7 tumors. Each mouse was euthanized when the
tumor size reached the end point or on day 60. aTime (days) to end point
(TTE). bTreated group (T) − PBS group (C) = difference between TTE
(days) of T vs. C (TGD). c(T − C)/C (%TGD). All of the data are represented
as average ± SEM and analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001).
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substantially reduced toxicity. With respect to NC size effects,
Cpt-NC50 was much more efficacious than Cpt-NC200 and Cpt-
NC20 against an s.c.-implanted xenograft primary tumor.
Metastatic cancer is regarded as an incurable disease by con-
ventional methods, including surgical resection, chemotherapy,
and radiation therapy, and responsible for over 90% of cancer-
related death (37). NM may offer new solutions for improving
the prevention or treatment of tumor metastases. Despite ex-
tensive studies on NMs for the treatment of primary tumors, very
few investigations have explored the efficacy of NMs against
tumor metastases, and there are no studies that characterize the
size effect of NMs on the efficacy against metastatic cancer.
After we showed that Cpt-NC50 was the most efficacious in a
breast primary tumor model, we went on to evaluate the size-
dependent efficacy of Cpt-NCs in inhibiting the 4T1 murine
breast cancer metastasis to lung tissues; 4T1 tumor is highly tu-
morigenic and invasive and can spontaneously metastasize to
distant sites, such as the lung parenchyma (38), and 4T1 cells,
which were luciferase-engineered for noninvasive monitoring of
tumor growth in live animals using the bioluminescence (BL)
imaging technique, were injected i.v. into BALB/c mice on day
0 to establish an experimental metastatic tumor model (39). The
mice were treated with different Cpt-NCs as well as irinotecan
starting from day 1 to examine the efficacy of metastasis in-
hibition (SI Appendix, Fig. S10). The BL imaging of the control
mice (PBS group) on days 8 and 12 confirmed the existence of
metastatic 4T1 tumors proliferating within lung parenchyma
(Fig. 4A). As shown in Fig. 4 A and C, 12 d post-tumor in-
oculation, the BL signal emitted from the lung tissues of mice
treated with PBS, Cpt-NC200, or Cpt-NC20 intensified rapidly
and progressively. There were essentially no difference in BL
intensities among the Cpt-NC200 and Cpt-NC20 groups and
the PBS group, suggesting very limited efficacy of these two NCs
for metastasis inhibition. However, the BL signal was markedly
lower in the mice treated with Cpt-NC50 and irinotecan and
increased at a much slower rate, suggesting that Cpt-NC50 exerted
greater anticancer activities compared with Cpt-NC20 and Cpt-
NC200, achieving comparable effects as free irinotecan (Fig. 4 A
and C).
To further analyze lung pathology both macroscopically and
microscopically, lung tissues were harvested from inoculated
mice for detailed gross and histopathological evaluation. Tu-
mor nodules on the surface of the lungs were counted man-
ually with the aid of dissecting microscopy (Fig. 4 B and D).
The results indicated that the treatment of Cpt-NC50 signif-
icantly reduced the number of macroscopic tumor nodules
(77.3 ± 9.3 per lung) compared with the PBS group (108.8 ±
9.8 per lung) (Fig. 4D), which was consistent with the BL
signal analysis (Fig. 4C). We also scaled the metastatic lungs
based on the percentage of lung surface covered by tumor
nodules (SI Appendix, Fig. S11B). The Cpt-NC50 group had
an average score (3.0 ± 0.4) that was comparable with that of
the irinotecan group (2.9 ± 0.2) and much lower than those of
the Cpt-NC200 (3.7 ± 0.4) and Cpt-NC20 (3.8 ± 0.2) groups
(SI Appendix, Fig. S11A). The results were further confirmed
by sectioning the lungs and performing the histopathological
analysis. Correlating with gross evaluation, there was a prom-
inent reduction in the number of microscopic tumor nodules
observed in the lung sections collected from the mice treated
with Cpt-NC50 (Fig. 4E). Tumor metastases were not ob-
served in other organs during the course of the study (SI
Appendix, Fig. S12). Collectively, Cpt-NC50 outperformed
Cpt-NC200 and Cpt-NC20 with respect to inhibiting the
progression of 4T1 cell metastasis to lung tissues, and Cpt-NC50
showed comparable anticancer activity with that of irinotecan. In
addition, the treatment of Cpt-NC50 did not cause any significant
change of body weight, food intake, or histological damage to
other tissues during the course of the study (SI Appendix, Figs.
S12 and S13), indicating that acute toxicity associated with Cpt-
NC50 in mice is clinically negligible. Similarly, as observed in
Fig. 4. Size-dependent antitumor efficacy in a metastatic tumor model. (A–E)
4T1 metastatic lung tumors were induced in mice by i.v. injection of luciferase-
engineered murine 4T1 breast cancer cells into BALB/c mice on day 0. The
mice were treated with i.v. injection of PBS (1×), Cpt-NC200 (20 mg Cpt/kg),
Cpt-NC50 (20 mg Cpt/kg), or Cpt-NC20 (20 mg Cpt/kg) and i.p. injection of
irinotecan (20 mg/kg) on days 1, 5, and 9 (n = 9–12). Representative (A) BL
images and (B) lung pictures at necropsy are shown for each treatment
group on day 12. (C) BL signals were analyzed to semiquantify 4T1 cell
metastasis progression using ImageJ. Photon emission is represented as in-
tegrated density, and the measuring threshold is empirically set as 5,000. (D)
Lungs were excised at necropsy and fixed in 10% (vol/vol) formalin. Tumor
nodules on the lungs were counted and averaged. (E) Fixed lung tissues
were embedded in paraffin, sectioned into 5-μm thickness, and then, stained
with H&E. Sectioned tissues were observed under a microscope with 50×
magnification. Representative images of the lung tissues are shown. T: tu-
mor tissue. (Scale bar: 200 μm.) (F) In vivo biodistribution study in BALB/c
mice bearing 4T1 metastatic tumors in lungs (n = 5). BALB/c mice with 4T1
metastatic tumors in lungs were injected i.v. with 64Cu-NC200, 64Cu-NC50, or
64Cu-NC20 to investigate the biodistribution. Mice were euthanized 24 h p.i.
(G) In vivo tumor penetration study in BALB/c mice bearing 4T1 metastatic
tumors in lungs (n = 3). BALB/c mice with 4T1 metastatic tumors were
injected i.v. with Rhd-NC200, Rhd-NC50, or Rhd-NC20. Mice were euthanized
24 h p.i. The lungs were sectioned in optimum cutting temperature com-
pound and stained with CD31 to indicate the blood vessels (green). Repre-
sentative images show the distribution of Rhd-NCs (red) in the lung tissues
with metastatic 4T1 tumors. The nuclei were stained with DAPI (blue). All of
the data are represented as average ± SEM and analyzed by one-way
ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).
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primary MCF-7 tumors, the accumulation of 64Cu-NC50 in
lungs with metastatic 4T1 tumors was 22.3% and 11.7% higher
than 64Cu-NC200 and 64Cu-NC20, respectively (Fig. 4F and SI
Appendix, Fig. S14). Interestingly, the accumulation of the NCs
of all sizes in lungs with metastatic tumors was significantly
higher than that in lungs without tumors, probably because of
tumor vascularity and cancer cell internalization (Fig. 4F). In
addition, Rhd-NC50 also showed increased retention in the lung
tissues with metastatic 4T1 tumors, which was evidenced by the
tissue section analyses compared with Rhd-NC20 and Rhd-
NC200 (Fig. 4G). The enhanced tumor accumulation of 50-nm
NCs in both primary and metastatic tumors likely contributes to
the improved anticancer efficacy observed in both tumor models.
In conclusion, our investigation using monodisperse drug–
silica NCs with discrete sizes provides clear theoretical and
experimental evidence that the size of NM plays a vital role in
determining its biological property and antitumor activity.
The 50-nm drug–silica NC outperforms its smaller (20 nm)
and larger (200 nm) analogs in overall tumor tissue accumu-
lation and retention, and thus, shows the highest efficacy
against both primary and metastatic tumors. Therefore, 50 nm
could be or could be close to the optimal size of the PEG-
coated anticancer drug–silica NC that balances extravasation,
inward permeation inside tumor tissues, tumor cell internalization,
and outward diffusion and clearance from tumor to retain the
highest effective drug concentrations in tumors. Many surface
PEGylated anticancer NMs are in various stages of preclinical or
clinical development. Because the size and the surface property
of an NM likely dictate its overall biological property, PEG-
coated NMs may share many similarities with respect to their
size dependency of biological activities. Our study and confir-
mation of the existence of the optimal size of the PEG-coated
drug–silica NC clearly show the importance of controlling the
size and dispersion of PEGylated NMs and the potential of
further improving their antitumor efficacy by identifying the
optimal size against a specific cancer. However, whether the
optimal size of other PEGylated NMs remains at or around 50
nm requires further study.
Materials and Methods
Cpt-NCs with controlled sizes were prepared as previously reported (24) and
used for all efficacy studies. Details describing preparation and character-
ization of size-controlled silica NCs; size-dependent biodistribution, tumor
penetration and clearance, and cellular internalization studies; size-
dependent efficacy studies in a primary tumor model; size-dependent
efficacy studies in a metastatic tumor model; and spatiotemporal mod-
eling of NP uptake into tumors can be found in SI Appendix.
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